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Terminology and definitions 
 
Bupr Bupropion 
Comparator The intervention used as an alternative to the investigated intervention 
Cost effective An intervention or program is called more cost effective if it leads to lower costs per 
effect than the alternative intervention, ie the comparator. This is reflected in the cost-effectiveness 
ratio (expressed as the costs of the intervention minus the costs of the alternative divided by the effects 
of the intervention minus the effects of the alternative). Cost effectiveness is a relative measure and it 
is impossible to call a program ‘cost effective’ without refering to a comparator.  
Cost-effectiveness analysis An analytic tool in which costs and effects of a program or intervention 
and at least one alternative are calculated and presented in a ratio of incremental costs to incremental 
effects. Effects are health outcomes, measured in natural effects or physical units, such as new patients 
prevented or life years gained. If health outcomes are measured in quality adjusted life years (QALYs), 
the method is also called cost-utility analysis.  
DDD Defined Daily Dose, used to measure medication use in a common unit. One DDD is the 
standard amount prescribed per day for the medications main indication. 
Direct costs Value of resources diverted from other use due to illness. Divided into direct medical 
costs (value of health care resources, e.g. drugs), and direct nonmedical costs, for instance 
transportation.  
Discounting The process of converting future costs or effects to their present value with the help of a 
discount rate.  
Dominant/dominated intervention Intervention A dominates intervention B (intervention A is 
dominant, intervention B is dominated) if A is more effective and less costly than B. 
Efficiency Resource input in relation to outcome, for instance health outcomes. One measure of 
efficiency in health care is cost effectiveness. 
H-MIS Short, low intensity counseling in a primary care setting, by the general practitioner, and/or his 
assistant. 
IC Intensive counseling 
Incremental costs/effects The difference in costs (effects) between the intervention and its 
alternative. 
Indirect costs Value of lost resources due to illness or death. Most important example is productivity 
costs, that is the costs of production lost due to absence from work.  
LYG Life years gained. A measure of health outcome which counts the difference in life expectancy 
with and without the intervention. This measure only takes account of reductions in mortality. 
Net costs/net savings Outcome if all costs and savings included in the evaluation are added together. 
Positive net costs imply negative net savings and vice versa.  
NRT Nicotine replacement therapy. 
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Present value The value to the decision maker now of outcomes (effects or costs) occurring in the 
future.  
Productivity costs Value of resources lost due to lost or impaired ability to work (both paid and 
unpaid) as a result of illness or death. 
Purchasing Power Parity Exchange rate used to compute results to different currencies, based on the 
price of a given, fixed, basket of goods.  
Quality adjusted life year (QALY) A measure of health outcome which assigns to each period of 
time a weight, corresponding to health-related quality of life during that period, where a weight of 1 
corresponds to optimal health and a weight of 0 corresponds to a health state judged equivalent to 
death; these are then aggregated across periods. This measure combines reductions in mortality and 
morbidity. 
TC Telephone counseling  
Transferability Degree to which (cost-effectiveness) results can be transferred from one setting, e.g. 
one country, to the other. 
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Abstract 
 
Objectives: To estimate the cost-effectiveness of five face-to-face smoking cessation 
interventions: 1) Telephone Counseling (TC), 2) Minimal counseling by a general practitioner 
(H-MIS), 3) Minimal counseling by a general practitioner combined with Nicotine 
Replacement Therapy (H-MIS+NRT), 4) Intensive Counseling combined with Nicotine 
Replacement Therapy (IC+NRT) and 5) Intensive Counseling combined with Bupropion 
(IC+Bupr), in terms of costs per quitter, costs per life-year gained and costs per quality-
adjusted life-year (QALY) gained. 
 
Methods: Scenarios on increased implementation of smoking cessation interventions were 
compared to current practice. Base-case scenarios assumed that one of the five interventions 
was implemented for a period of either 1 year, 10 years or 75 years and reached 25% of the 
smokers. A computer simulation model, the RIVM Chronic Disease Model, was used to 
project future gains in life-years and Quality Adjusted Life Years (QALYs), and savings of 
health care costs from a decrease in the incidence of smoking-related diseases. Regardless of 
the duration for which the intervention was implemented, our time horizon was 75 years, i.e. 
costs and effects were studied over a period of 75 years. Intervention costs were computed 
based on bottom up estimates of resource use and costs per unit of resource use. Cost 
calculations of smoking cessation interventions were carried out from a health care 
perspective, i.e. total direct medical costs were calculated based on estimates of real resource 
use. Effectiveness in terms of cessation rates was obtained from Cochrane meta-analyses. For 
the base-case scenarios, future costs and effects were discounted at an annual percentage of 
4%. Incremental cost-effectiveness ratios were calculated as: (additional intervention costs 
minus the savings from a reduced incidence of smoking related diseases) / (gain in health 
outcomes). A series of one-way sensitivity analyses were performed to assess the robustness 
of the cost-effectiveness ratios with regard to variations in cessation rates, intervention costs, 
discount rates, time horizon, and the percentage of smokers reached by the intervention. 
 
Results: Base-case estimates for costs per quitter ranged from €443 for H-MIS to €2800 for 
IC+NRT. Compared to current practice H-MIS is a dominant intervention regardless of the 
duration of implementation. This means that H-MIS not only generates gains in life years and 
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QALYs but its saving are higher than its intervention costs. The four other interventions had 
relatively low cost-effectiveness ratios when compared to many other preventive 
interventions. When implementing each of the interventions for a period of 75 years, their 
ratios varied from about €1400 per life year gained for TC to €6200 per life year gained for 
IC+NRT. Incremental costs per QALY gained were €1100 for TC, €1400 for H-MIS+NRT, 
€3400 for IC+Bupr, and €4,900 for IC+NRT. Results were most sensitive to the rate of 
discounting. 
 
Conclusions: All five smoking-cessation interventions are very cost-effective, with ratios far 
below €20000. H-MIS is even cost saving.  
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Introduction. 
 
Smoking is a leading cause of preventable morbidity and mortality in terms of increased risks 
of many diseases, loss of quality of life and loss of life-years. In 2001, 30% of the Dutch 
population of 15 years and older was a current smoker and 16% of the total mortality in that 
same year was attributable to smoking.1 Smoking incurs high costs to society. The World 
Bank estimated that 6% to 15% of the health care costs were attributable to smoking in 
developed countries.2  
For many smokers, it is hard to quit smoking on will power alone. Only 3-7% of the smokers 
who attempts to stop smoking on will power, is still abstinent after one year.3-5 A wide range 
of policy measures and therapies is available to increase this rate, varying from price increases 
by taxation, media campaigns, or self-help manuals, to intensive individual counseling 
combined with pharmaceutical therapies.5,6 For smoking cessation interventions administered 
by medical professionals, the percentage of quitters ranges from 7% up to 24%.5  
Cost-effectiveness analysis is used to inform policy makers about the economic and health 
implications of medical programs, e.g. smoking cessation interventions. It compares the costs 
and effects of a program or intervention to at least one alternative (comparator). Results are 
usually presented in a ratio of incremental costs to incremental effects. The lower this ratio, 
the more cost effective it is to implement the investigated intervention. That is, the more 
health effects are obtained for given expenditures. Some interventions turn out to be 
dominant, because they are less costly and, at the same time, generate more health effects than 
their comparator. Other interventions result in better health but at additional costs. No general 
agreed upon threshold value for cost-effectiveness ratios exists. However, in the Netherlands, 
for preventive interventions such as smoking cessation, €20000 per life year gained is an 
often-used limit for cost effectiveness. This figure was first introduced in the 1998 
Cholesterol consensus7,8, in the form of a NLG 40000 threshold. Compared to this threshold, 
the smoking cessation interventions are very cost-effective.9,10  
 
A summary of results from the international literature on cost-effectiveness of smoking 
cessation interventions can be found in appendix A. Costs per life-year gained varied between 
€215 and €10,380 when the figures from foreign studies were converted into Dutch currency, 
using Purchasing Power Parity data11 and then updated to the year 2000 using consumer price 
indices. The majority of studies reported cost-effectiveness ratios around €2,500 per life-year 
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gained. These figures should be interpreted with care, because the transfer of results from 
economic studies between countries is difficult. Part of the reviewed cost-effectiveness 
studies calculated costs per life-year gained or costs per quality-adjusted life-year (QALYs) 
gained.10,12-23 Few cost-effectiveness studies included savings in costs of care from avoided 
smoking-related morbidity. Incremental cost-effectiveness ratios were scarcely reported. No 
complete Dutch cost-effectiveness studies of face-to face smoking cessation interventions 
reporting costs per life year gained and QALY were found in our literature review. The Dutch 
Health Care Insurance Board (CVZ) did a quick scan of available information and estimated 
costs per quitter for a mix of cessation methods at around €1300.6 A paper by Mudde and co-
authors24 analysed the cost effectiveness of a community intervention offering a choice 
between a self-help manual and a group program. They reported costs per quitter around 
€860. Recent work on the cost effectiveness of experimental coverage of smoking cessation 
interventions reported costs per additional quitter of €470.25  
 
The present study aims to examine cost-effectiveness for a subset of smoking cessation 
interventions, namely face-to-face smoking cessation interventions administered by medical 
professionals with proven effectiveness in terms of cessation rates. Five different cessation 
interventions were compared to current practice to report incremental cost-effectiveness ratios 
for the Netherlands: 1) short, low intensity counseling in a primary care setting (H-MIS), 2) 
Minimal counseling and nicotine replacement therapy (H-MIS+NRT), 3) Intensive counseling 
and NRT (IC+NRT), 4) Intensive counseling and Bupropion (IC+Bupr), and 5) Telephone 
counseling (TC).  
Cost-effectiveness was expressed in terms of costs per quitter, costs per life-year gained and 
costs per QALY gained. A computer simulation model, the RIVM-Chronic Disease Model,26 
was used to project the future gains in life-years and QALYs, and the savings in health care 
costs, that result from a decrease in the incidence of eleven smoking-related diseases. 
Different scenarios of increased implementation of smoking cessation interventions were 
considered, for all smokers in the population and for smokers in specific age groups. Costs 
and effects of the increased implementation scenarios were compared to costs and effects of a 
current practice scenario to determine incremental cost-effectiveness ratios. Sensitivity 
analyses were performed to assess the robustness of the cost-effectiveness ratios with regard 
to variations in resource use, effectiveness, time horizon, program size and discount rates. 
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The current study did not analyse the total costs of smoking. In addition to the cost-
effectiveness data presented below, so called “cost of illness”, also called “burden of disease” 
studies analyze the total -financial- burden of smoking. References to this kind of studies for 
the Netherlands are 27,28,29. International data can be found in Jha and Chaloupka2 and at the 
World Health Organisation. 
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Methods 
 
To calculate Dutch cost-effectiveness figures, the following approach was used: 
First, the interventions and scenarios evaluated were selected. The scenarios contain the 
implementation of the intervention to a given percentage of smokers for a given number of 
years over a given time horizon. Current practice was described as the comparator scenario. 
Second, the effectiveness in terms of cessation rates was estimated. Third, the costs per 
smoker for these interventions were calculated. Combining costs and effects resulted in costs 
per quitter. Fourth, cessation rates were translated into life-years gained, QALYs gained, and 
savings in health care costs with the help of a dynamic model to compute projections for the 
different intervention scenarios. This included the modeling of the current practice 
comparator scenario. Finally, costs per life year gained and costs per QALY gained were 
computed. In a sensitivity analysis, the effects on the cost-effectiveness results of variations in 
resource use, effectiveness, the time horizon considered, the percentage of smokers reached, 
the duration of the intervention, and the discount rates, were computed. 
 
Smoking cessation interventions 
 
This study focussed on face-to-face smoking cessation programs, administered by medical 
professionals or educated smoking cessation counselors. They had to have a proven 
effectiveness in terms of cessation rates from international meta-analyses9,30-32 or Dutch trial 
data 33,34 and be currently available in the Netherlands.5,6 Given the goals of the Dutch 
Ministry of Health as phrased by the Partnership Stop Smoking (a reduction to 28% smokers 
in 2004), only the most effective interventions, with a 12-months continuous abstinence 
cessation rate above 6%, were included.  
 
Based on these criteria, the following smoking cessation interventions were selected:  
1. H-MIS: Minimal counseling by a general practitioner (GP) and/or a GP-assistant in one or 
two consultations with a total length of 12 minutes. 33,35 
2. H-MIS+NRT: Minimal counseling combined with nicotine patches or gum, for a period of 
eight weeks.5,30 
3. IC+NRT: Intensive counseling by a trained counsellor in combination with nicotine 
patches or gum for a period of 12 weeks. We assumed the counseling would be done by a 
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trained lung nurse for a total of 90 minutes after a brief stop advice from a lung physician 
in either an outpatient or inpatient setting.5,30,36 
4. IC+Bupr: IC in combination with Bupropion for a period of nine weeks.5,31,36 
5. TC: Tailoring telephone counseling as currently provided by the Dutch Foundation on 
Smoking and Health (STIVORO), consisting of one intake call of 30 minutes and six 
follow-up calls of each 15 minutes, based on a (computerised) questionnaire completed by 
the potential quitters.5,32,34,37 
 
Scenarios 
 
The term scenario refers to offering one of the five interventions to a given percentage of 
smokers for a given number of years over a given time horizon. Base-case scenarios assume 
that the intervention reaches 25% of all smokers, because we made the assumption that 25% 
of all smokers were in the preparation state (truly ready to make a serious quit attempt). This 
percentage is close to the 21% of current smokers who indicate that they would be willing to 
stop in the following year.38  
Base-case scenarios assumed that the intervention was implemented on a permanent basis for 
periods of 1 year, 10 years and during the whole time horizon of 75 years. Hence, an 
intervention reaches 25% of all current smokers in every year for which it was implemented. 
After the implementation period the cessation rates return to current practice levels. In 
addition, scenarios for offering the interventions to 25% of all smokers aged 25 years and 
older, 35 years and older, 45 years and older, and 65 years and older, were analyzed. 
For all scenarios the model projected numbers of smokers and quitters, morbidity, mortality 
and health care costs for 11 smoking related diseases. These projections were compared to a 
projection based on current practice to determine cost-effectiveness ratios. Our time horizon 
was 75 years to enable the full effect of smoking cessation to become visible. 
 
Current practice 
 
Current practice (CP) was defined as the currently applied mix of the above-mentioned five 
interventions and all other interventions directed at smoking cessation. The estimated current 
use of the selected interventions is shown in Table 1. In total about 1.3 % of smokers used one 
of the selected interventions. The smoking cessation rates in the current practice scenario 
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were based on STIVORO data (1998-1999)39-41 and three Dutch cohort studies.42-44 The 
average cessation rate over all gender and age classes was 3.4%. 
 
Table 1: Current Practice: percentage of smokers that used the interventions in 2000 in the Netherlands 
Intervention Use of the intervention as a 
percentage of the total 
number of smokers in the 
Netherlands (4.5 10^6) 
Background 
H-MIS 0.36% 30% of the GPs (6,542 full-time equivalents) provided minimal 
GP counseling 45 46 
76% of the Dutch population contacted their GP at least once a 
year 1 
the average number of contacts for minimal GP counseling was 
estimated 0.75 per week per GP, of which roughly 71% was a 
first consultation 47 
35% of the GPs provided minimal counseling without advice to 
use NRT 47 
H-MIS+NRT 0.66% 
 
65% of the GPs often to always advised to use NRT in 
combination with minimal counseling 47  
IC+NRT 0.16% 27% of the lung physicians (number of full-time equivalents: 
375) provided intensive counseling 48  
the average number of contacts for counseling by a lung 
physician was estimated 3.1 per week per physician 48  
52% of the lung physicians often to always advised to use NRT 
in combination with intensive counseling 48  
IC+Bupr 0.14% 
 
48% of the lung physicians often to always advised to use 
Bupropion in combination with intensive counseling 48  
TC 0.026% in 2001, 1.2 thousand smokers were reached by telephone 
counseling at STIVORO 37 
 
 
Effectiveness  
 
Effectiveness in terms of cessation rates was obtained from twelve months prolonged 
abstinence rates given in a recent Dutch review,5 and from Dutch trials.33,34 Table 2 lists these 
abstinence rates for the different smoking cessation interventions. Effectiveness of minimal 
GP counseling was based on the available Dutch effectiveness research only.33 For telephone 
counseling at STIVORO, Cochrane data were pooled with a Dutch evaluation study34. For the 
remaining interventions, no Dutch effectiveness research was available and the figures given 
in the Dutch review study were based on international randomized controlled trials as 
included in Cochrane reviews.  
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Table 2: Twelve months continuous abstinence rates for different smoking cessation interventions  
Intervention Abstinence 
rate 
95%-CI Source 
Current Practice 3.4 %  STIVORO data and three Dutch cohort studies39-41,42-44 
H-MIS 7.9% * 4.7% - 11.1% 1 Dutch randomized controlled trial (RCT)33 
H-MIS+NRT  12.7% 11.9% - 13.5% 17 international RCTs5,30  
IC+NRT  15.1% 14.1% - 16.1% 26 international RCTs5,30 
IC+Bupr. 17.2% 14.0% - 20.4% 4 international RCTs5,31 
TC 7.6% 6.9% - 8.3% 9 international RCTs5,32and 1 Dutch evaluation study34 
*Cessation rate in trial: 8.2%. 9% used H-MIS in combination with nicotine gum. Cessation rate for minimal GP counseling: 
8.2-(0.09*11.0)/0.91=7.9% 
 
 
Intervention costs 
 
The viewpoint in this cost-effectiveness analysis was that of the Ministry of Health and, 
therefore, intervention costs included direct medical costs that were based on bottom up 
estimates of real resource use and costs per unit. All costs were expressed in Euros, for the 
start year 2000. For future costs, we used these same figures.  
Table 3 presents the calculated costs of the different smoking cessation interventions. For 
current practice, resource use was based on Dutch empirical data. For the interventions, 
resource use was based on Dutch practice guidelines 35,36 and (for the duration of NRT and 
Bupropion) on the international trials that were used in the Cochrane meta analyses 
underlying the effectiveness data, to estimate the costs of an “optimal” implementation of the 
smoking cessation interventions in line with the effectiveness figures. 
Costs per unit were combined with resource use to estimate intervention costs. For the costs 
of minimal GP counseling, we used the standard cost of a GP consultation from the Dutch 
guideline for economic evaluations.50 This standard cost included overhead costs. We 
assumed that one GP consultation lasts 10 minutes and calculated costs per minute. Material 
costs for self-help manuals were added separately.37 
To compute the costs of current practice for NRT and Bupropion, the mean number of 
prescriptions per person51 was multiplied by the mean gross costs per prescription.52 Costs of 
adverse effects were assumed to be negligible.53 For the pharmacological costs in the 
increased implementation scenarios, average costs per defined daily dosis (DDD)52,54 were 
multiplied by the total duration of use as estimated from international meta-analyses.30,31 For 
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intensive counseling and telephone counseling, the salary of a counsellor (respiratory nurse, 
or trained counsellor at STIVORO, respectively) per unit of time was multiplied with 
counseling time.36,49 This included material and overhead costs. In addition, the standard costs 
of a lung physician consultation50 were used to find the costs of a two minutes stop advice. 
Material costs for self-help manuals were added separately.37 The base-case estimates of the 
costs per smoker for the different smoking cessation interventions were: Є21 for H-MIS, 
Є163 for H-MIS+NRT, Є349 for IC+NRT, Є334 for IC+Bupr and Є70 for telephone 
counseling. 
 
Table 3: Costs of the components of smoking cessation interventions for the current practice scenario and 
for the increased implementation scenarios (Euro, year 2000 price level) 
Component Volume Unit costs Total costs per quitter 
  Current 
practice 
Intervention 
programs 
 Current 
practice 
Intervention 
programs 
H-MIS GP time (minutes) 6.5 12 1.70# 11 20 
 Self-help manuals 1.0 1.0 1.00 1 1 
       
NRT Prescriptions 1.6  20* 32  
 Defined daily doses (DDDs) 
of  patches or gum 
(combined with H-MIS) ** 
 65.01 2.18*  142 
 DDDs patches or gum 
(combined with IC) *** 
 80 2.18*  175 
       
IC Lung physician time 
(minutes) 
2 2 3.29# 7 7 
 Lung nurse time (minutes) 110 90 1.85# 204 167 
 Self-help manuals 1.0 1.0 1.00 1 1 
       
Bupr Prescriptions 1.5  47* 71  
 DDDs Bupropion****   63 2.53*  160 
       
TC Counsellor time (minutes) 60 120 0.43 26 52 
 Overhead (as cost per 
minute) 
60 120 0.15 9 18 
*Total gross price.** One DDD equals 14 mg for patches. ***One DDD equals 30 mg for gum. ****One DDD equals 300 mg for 
Bupropion. #Includes overhead.   
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Costs of smoking related diseases 
 
We included eleven smoking-related diseases, i.e., coronary heart disease (myocardial 
infarction and other coronary heart disease), stroke, COPD, lung cancer, larynx cancer, oral 
cavity cancer, oesophagus cancer, pancreas cancer, bladder cancer and kidney cancer. Health 
care costs for these diseases were obtained from a Dutch cost-of-illness study that allocated 
total direct costs of health care using a top-down approach.29 These 11 disease accounted for 
9% of the total costs of health care in the Netherlands in 1999.29 
 
Model and input data 
 
A computer simulation model that was developed at the National Institute of Public Health 
and the Environment (RIVM) in Bilthoven, the Chronic Disease Model,26 was used to 
translate effects in terms of increased cessation rates for groups of smokers into future gains 
in life-years, QALYs, and savings of health care costs. This dynamic population model 
describes the life course of parallel Dutch population cohorts annually over time. We 
simulated changes in smoking prevalence rates and the resulting changes in incidence rates of 
smoking-related chronic diseases, stratified by gender and by 5-year age-classes. The model 
was described in more detail elsewhere26,55,56 and has been used previously to evaluate the 
effects of smoking cessation scenarios.28,57-59 We choose 2000 as the start year of the 
simulations.  
 
Input data on birth, migration and all-cause mortality rates came from Statistics Netherlands.1 
Disease-specific input data of the Chronic Disease Model included prevalence, incidence, and 
mortality rates of smoking-related diseases,55,56 risk ratios for incidence of these diseases for 
current and former smokers 60 and quality-of-life weights for life-years with disease.60,61 Table 
4 summarises these data, and gives incidence rates, and quality-of-life weights for eleven 
smoking-related diseases. For co-morbidity of 2 diseases at maximum, the assumption was 
made that risk ratios were multiplicative, conditional on smoking status, and that the quality-
of-life weight for a combination of diseases is equal to the lowest quality-of-life weight of one 
of these diseases.  
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Table 4: Incidence rates, risk ratios for incidence for current and former smokers and quality-of-life 
weights of eleven smoking-related diseases, stratified by gender  
Disease  Incidence rates 
(per 1000) 55,56 
RRs for incidence for current and former 
smokers * 60 
Quality-of-life 
weights 60,61 
  Current smokers Former smokers  
 Men Women Men Women Men Women Men Women 
Myocardial infarction 3.2 1.7 2.9 3.2 1.6 1.3 0.29 0.29 
Coronary heart disease 3.1 2.2 2.9 3.2 1.6 1.3 0.29 0.29 
Stroke 2.0 2.3 3.3 3.8 1.3 1.4 0.61 0.61 
COPD 2.4 1.4 13.1 11.8 10.7 7.9 0.31 0.31 
Lung cancer 1.0 0.23 26.8 14.2 10.6 4.5 0.43 0.43 
Larynx cancer 0.083 0.014 10.5 17.8 5.2 11.9 0.12 0.12 
Oral cavity cancer 0.12 0.058 27.5 5.6 8.8 2.9 0.12 0.12 
Oesophagus cancer 0.091 0.042 7.6 10.3 5.8 3.2 0.73 0.73 
Pancreas cancer 0.092 0.088 2.1 2.3 1.1 1.8 0.51 0.56 
Bladder cancer 0.22 0.065 2.9 1.9 2.6 1.9 0.09 0.11 
Kidney cancer 0.11 0.078 3.0 2.0 2.1 1.9 0.24 0.38 
 
 
Prevalence rates of current and former smokers in the Netherlands were based on yearly 
population monitoring studies of STIVORO for the time period 1997-2000.37,39-41,62 
Transition probabilities included start, cessation and restart probabilities. Cessation 
probabilities for the current practice scenario were based on a weighted average of STIVORO 
data over the period 1998-1999 39-41 and data from three Dutch cohort studies 42-44 and were 
an approximation of 12 months continuous abstinence. Start and restart probabilities were 
estimated by combining smoking prevalence rates from STIVORO over the period 1997-2000 
with the cessation probabilities. Table 5 summarizes model input on smoking and presents 
smoking transition probabilities that were used for the current practice scenario. Age and 
gender specific current practice cessation rates were multiplied with the ratio of the overall 
cessation rates reported for the different interventions (Table 2) and the overall current 
practice rate for the target group of smokers (target groups were 25% of all smokers, and 25% 
of smokers in selected age groups) to compute cessation rates for the intervention scenarios. 
Start and relapse rates were not changed for the intervention scenarios.  
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Table 5: Start, cessation and restart probabilities for the current practice scenario, stratified by gender 
and by 5 year age-class. 37,39-41,42-44,62 
Age-class Men Women 
 Start  Cessation  Restart  Start  Cessation  Restart  
       
0 – 4 0 0 0 0 0 0 
5 – 9 0 0 0 0 0 0 
10 – 14 0.028 0.007 0 0.037 0.007 0 
15 – 19 0.046 0.015 0 0.039 0.015 0 
20 – 24 0.042 0.018 0.031 0.016 0.027 0.014 
25 – 29 0.006 0.025 0.097 0 0.033 0.053 
30 – 34 0 0.031 0.129 0 0.038 0.097 
35 – 39 0 0.036 0.114 0 0.040 0.098 
40 – 44 0 0.039 0.099 0 0.041 0.114 
45 – 49 0 0.042 0.085 0 0.042 0.099 
50 – 54 0 0.045 0.070 0 0.043 0.084 
55 – 59 0 0.048 0.055 0 0.043 0.069 
60 – 64 0 0.049 0.040 0 0.044 0.055 
65 – 69 0 0.049 0.025 0 0.046 0.040 
70 – 74 0 0.047 0.010 0 0.051 0.025 
75 – 79 0 0.047 0 0 0.051 0.010 
80 – 84 0 0.047 0 0 0.051 0 
85 + 0 0.047 0 0 0.051 0 
Mean 0.007 0.033 0.042 0.005 0.034 0.042 
 
 
Cost-effectiveness 
 
Costs per smoker were multiplied by the total number of smokers and by the percentage of 
smokers receiving the smoking cessation intervention, to compute total intervention costs for 
the increased implementation scenarios. For the current practice scenario, costs per smoker 
were multiplied by the total number of smokers which was multiplied with the percentage of 
smokers reached by the different smoking cessation interventions (Table 1). The difference 
between these two resulted in the additional intervention costs. To compute costs per life-year 
or QALY gained, the cost savings from avoided smoking-related diseases were subtracted 
from the additional intervention costs. Additional quitters, life years, or QALYs were 
computed as the difference between the number of quitters, life years, or QALYs under the 
intervention scenario and the current practice scenario.  
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Cost-effectiveness ratios for each intervention compared to current practice were calculated 
by dividing the difference in costs by the difference in the number of quitters, life-years, or 
QALYs. Base-case estimates of costs per QALY and life-year gained included cost savings 
from reduced health care costs for smoking related diseases, but we also computed the ratio of 
intervention costs to the difference in QALYs or life-years, to have very conservative 
estimates of the cost-effectiveness ratios. Future costs and effects were discounted at the 
Dutch standard annual percentage of 4%.63  
 
Sensitivity analysis 
 
A series of one-way sensitivity analyses was carried out to investigate the robustness of the 
cost-effectiveness ratios with regard to variations in cessation rates, intervention costs, 
discount rates, time horizon, and the percentage of smokers reached by the intervention. 
Cessation rates were varied by their 95%-confidence limits (see Table 2). Intervention costs 
were varied from minimum to maximum estimates of resource use. These are shown in Table 
6. Discount rates on costs and effects of 0, 3 and 5% were used, and a discount rate of 4% for 
costs combined with 0% for effects. The percentage of smokers that was offered the 
intervention was varied from the base-case 25% to 10% and 50% of all smokers. Finally, 
results were computed for time horizons of 20, 30 and 50 years. 
 
Table 6: Minimum and mMaximum resource use, used in sensitivity analyses 
Component Resource use  Min. Base-case Max. 
H-MIS GP time (minutes) 3.0 12 20 
 
NRT DDDs patches or gum (combined with H-MIS) **49 65 141 
 DDDs patches or gum (combined with IC) *** 70 80 93 
 Duration NRT in weeks (combined with H-MIS) 7.4 7.8 16 
 Duration NRT in weeks (combined with IC)  11 12 14 
 
IC Lung nurse time (minutes) 40 90 110 
 
Bupr DDDs Bupropion****  49 63 84 
 Duration Bupr in weeks  7 9 12 
 
TC Counsellor time (minutes) 90 120 150 
** One DDD equals 14 mg for patches. ***One DDD equals 30 mg for gum. ****One DDD equals 300 mg for 
Bupropion. 
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Results 
 
Cost per quitter 
 
Table 7 shows total intervention costs as well as cost-effectiveness ratios for the year 2000. 
Costs per quitter included only intervention costs and ranged from about €443 for minimal GP 
counseling to about €2800 for intensive counseling with nicotine patches or gum.  
 
Table 7: Number of additional quitters, total additional intervention costs and costs per quitter for the 
increased implementation scenarios compared to the current practice scenario for the starting year 2000 
(EURO, year 2000 price level) 
Intervention Additional quitters (*103) Intervention costs (*106) Costs per quitter 
H-MIS 53.4 23.7 443 
H-MIS+NRT 111 181 1,630 
IC+NRT 140 387 2,800 
IC+Bupr. 165 370 2,240 
TC 49.7 77.7 1,560 
 
 
Cost per life year and cost per QALY 
 
Table 8 shows the estimates of cumulative costs and effects over a period of 75 year and the 
resulting cost-effectiveness ratios in terms of life years and QALYs gained when the smoking 
cessation interventions are offered for a period of 1, 10 and 75 years. 
H-MIS was a dominant strategy compared to current practice, regardless of whether the 
intervention is offered for 1, 10 or 75 years. For a 75-year implementation period, the absolute 
gain in life years and QALYs and the savings in costs for not having to treat smoking related 
disease were highest, but the intervention costs were also highest. For H-MIS about 330,000 
life years or 410,000 QALYs were gained. The number of QALYs gained includes morbidity 
changes and was therefore higher. Intervention costs were about €520.1 million and about 
€1.4 billion in health care costs for smoking related diseases were saved. Therefore, 
implementing H-MIS on a permanent basis for 25% of all smokers would save more than it 
costs. 
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The four other interventions yielded higher costs than savings and cost-effectiveness ratios 
were calculated. For example, implementation of IC+NRT for a period of 75 years would 
result in a gain of about 740,000 life years or about 940,000 QALYs. Intervention costs were 
about €7.8 billion while savings were about €3.2 billion, resulting in net additional costs of 
about €4.6 billion. Dividing the additional costs by the gain in health, costs per life year 
gained and per QALY gained were estimated to be about €6200 and €4900 respectively. 
The 1 and 10 year implementation scenarios show the effects of shorter than permanent 
implementation. Total intervention costs as well as savings and gains in life years and QALYs 
were of course much lower. The cost-effectiveness ratios were not very much affected by the 
choice of the implementation period.  
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Table 8: Base-case estimates of number of life-years and QALYs gained, total additional intervention 
costs, total savings, and cost-effectiveness: costs per life-year gained and costs per QALY gained for the 
different scenarios cumulative for the years 2000-2075, discounted at 4% for both costs and effects 
(EURO, year 2000 price level). 
Intervention LYs 
gained* 
(*104 ) 
QALYs 
gained** 
(*104) 
Intervention 
costs*** (*109)  
Savings from 
prevented 
diseases**** 
(*109) 
Costs 
per LY 
gained 
Costs per 
QALY gained 
1 year implementation 
H-MIS 1.4 1.7 0.023 0.057 † † 
H-MIS+NRT 2.8 3.6 0.18 0.12 2300 1700 
IC+NRT 3.5 4.5 0.39 0.15 6800 5200 
IC+Bupr. 4.1 5.3 0.37 0.17 4700 3600 
TC 1.2 1.6 0.077 0.053 2000 1500 
10 year implementation 
H-MIS 12 15 0.19 0.50 † † 
H-MIS+NRT 23 30 1.4 0.98 1900 1500 
IC+NRT 29 37 3.0 1.2 6300 4900 
IC+Bupr. 33 43 2.8 1.4 4400 3400 
TC 11 14 0.64 0.46 1600 1200 
Permanent implementation 
H-MIS 33 41 0.52 1.4 † † 
H-MIS+NRT 62 78 3.8 2.7 1800 1400 
IC+NRT 74 94 7.8 3.2 6200 4900 
IC+Bupr. 84 110 7.3 3.6 4300 3400 
TC 31 38 1.7 1.3 1400 1100 
* Compared to a cumulative total of 412.10^6 life-years from the current practice scenario.** Compared to a cumulative total of 392.10^6  
QALYs from the current practice scenario.*** Compared to cumulative costs of continued current practice of 120. 10^6 EURO. **** 
Compared to cumulative costs of care of 142.10^9 EURO from the current practice scenario.† Minimal GP counseling dominated current 
practice, due to cost savings and higher effects. 
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Targeting interventions to age groups 
 
Table 9 presents cost-effectiveness ratios for the permanent implementation scenarios targeted 
to specific age groups for IC+Bupr. The results for all other interventions showed a similar 
pattern. Cost-effectiveness ratios became more favorable when reaching the older population. 
Costs per QALY gained compared to current practice were about €2300 for the group of 
smokers 25 years and older (this is 85% of all smokers), while IC+Bupr was cost saving when 
applied in a scenario reaching 25% of smokers aged 65 years and older (i.e. 10% of all 
smokers). Total costs and effects were obviously much lower in the latter case. 
 
Table 9: Number of life-years and QALYs gained, total additional intervention costs, total savings, and 
cost-effectiveness: costs per life-year gained and costs per QALY gained for IC plus Bupropion, for 
different age groups, cumulative for the years 2000-2075, discounted at 4% for both costs and effects 
(EURO, year 2000 price level). 
Permanent 
implementati
on of 
IC+Bupr for 
smokers 
from the age 
groups: 
LYs gained* 
(*104) 
QALYs 
gained** 
(*104) 
Intervention 
costs*** 
(*109) 
Savings  of not 
having to treat 
smoking-related 
disease**** 
(*109) 
Costs per 
LY 
gained 
Costs per 
QALY gained 
all smokers 84 110 7.3 3.6 4300 3400 
25+ 84 110 6.1 3.6 3000 2300 
45+  76 91 3.3 3.2 120 100 
65+  24 19 0.86 0.90 † † 
* Compared to a cumulative total of 412.10^6 life-years from the current practice scenario.** Compared to a cumulative total of 392.10^6  
QALYs from the current practice scenario.*** Compared to cumulative costs of continued current practice of 120. 10^6 EURO.       **** 
Compared to cumulative costs of care of 142.10^9 EURO from the current practice scenario. † IC+Bupr for 65+ dominated current 
practice, due to cost savings and higher effects. 
 
 
Effects and costs over time  
 
In the current practice scenario, the number of smokers declined from 4.43 million in 2000 to 
3.74 million in 2075, which were 32% and 25% of the Dutch population of 10 years and older 
respectively. For the intervention scenarios reaching 25% of the smokers, the number of 
smokers declined to 2.92 million in 2075 for permanent implementation of intensive 
 counseling with Bupropion at maximum. For the intervention scenarios of 1 and 10 years 
implementation, effects gradually disappeared after the intervention stopped and the number 
of smokers in 2075 was 3.74 million like in the current practice scenario. The maximum 
difference between the number of smokers in current practice and that in the intervention 
scenarios was 23% for permanent implementation for 75 years, 19% for 10 year 
implementation and 4% for 1 year implementation.  
In all scenarios, a lag time of about 20 years between an increased implementation of smoking 
cessation interventions and the full gain in life-years and QALYs could be observed. Figure 1 
shows the undiscounted number of QALYs gained for the base case intervention scenarios 
with 10 years of implementation, compared to current practice, in each of the years 2000 to 
2075. The –discounted at 4%- cumulative gain in QALYs ranged from 140,000 for telephone 
counseling to 430,000 for intensive counseling with Bupropion. 
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H-MIS H-MIS+NRT IC+NRT IC+Bupr TCFigure 1: Number of QALYs gained in each individual year for the increased implementation 
scenarios, compared with current practice, over the years 2000-2075, 0% discounting, 10 year
implementation period 25
e 2 shows the undiscounted cumulative savings in health care costs for smoking related 
ses and the additional intervention costs for the base-case scenario in which H-
NRT is offered for 1 year, compared to current practice. Of course, intervention costs 
 only in year 1. The break-even point is reached after 25 years, when cumulative savings 
e equal to the intervention costs.   
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Sensitivity analysis 
Figure 3 presents costs per quitter plus uncertainty ranges over resource use and cessation 
rates (Table 2, Table 6).  Figure 4 presents gains in total costs (i.e. including cost savings 
from reductions in the incidence of 11 smoking related diseases) and QALYs plus uncertainty 
ranges over resource use and cessation rates, for permanent implementation of the smoking 
cessation interventions compared to current practice (75 year time horizon, net present value 
at 4% discounting). Changes in cessation rates do not only lead to changes in QALYs gained 
but also to changes in the incidence of smoking related diseases and hence to changes in total 
additional costs. This explains why the horizontal confidence lines in figure 4 are not 
completely horizontal, but slightly diagonal. The slope of the imaginary lines from the origin 
(the current practice scenario) to the point estimates represents the incremental cost-
effectiveness ratios, compared to current practice. The slope of the imaginary lines between 
two point estimates represents the incremental cost-effectiveness for the interventions 
compared to each other.  
The relative large uncertainty about the effectiveness of H-MIS is reflected by the relatively 
wide horizontal uncertainty range. Nevertheless, the result that H-MIS is a cost saving 
intervention is robust for uncertainties in resource use and effects. Uncertainty ranges overlap, 
so that the dominance of intensive counseling with Bupropion over intensive counseling with 
NRT is quite uncertain, while that of minimal GP counseling over telephone counseling is 
Figure 2 :Cumulative intervention costs and savings in health care costs for base-case 1 year 
implementation of H-MIS+NRT, compared with current practice, over the years 2000-2075, 0% 
discounting. 
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also uncertain. Besides, due to the large uncertainty range in costs, it may well be that 
minimal counseling with NRT is also dominated by either intensive counseling with NRT or 
intensive counseling with Bupropion.  
 
 
Figure 3. Additional intervention costs in the first year and number of additional quitters in the first year 
for the 75 year intervention scenarios compared to current practice and the ranges in additional costs and 
quitters based on the sensitivity analyses. 
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Figure 4. Total additional costs and total QALYs gained for the 75 year intervention scenarios compared 
to current practice and the ranges in costs and effects based on the sensitivity analyses, cumulative over 
the years 2000-2075. Discount rate was 4%, time horizon 75 year. 
  
 
 
Table 10 shows incremental cost-effectiveness ratios for different discount rates for costs and 
effects, compared to current practice, for base-case 1, 10 and 75 years implementation 
scenarios. Discounting had a considerable effect on cost-effectiveness ratios, reducing the 
impact of both future savings in health care costs and future health effects. 
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Table 10: Incremental costs per QALY gained for the increased implementation scenarios for different 
discount rates for both costs and effects, cumulative for the period 2000-2075 (EURO, year 2000 price 
level). 
Intervention Costs per QALY for different discount rates 
 Discount rate for 
costs and effects 0% 
Discount rate for 
costs and effects 3% 
Discount rate for 
costs and effects 5% 
Discount rate for 
costs 4% and for 
effects 0% 
1 year implementation  
H-MIS † † † † 
H-MIS+NRT 54 1200 2400 820 
IC+NRT 1700 4100 6500 2500 
IC+Bupr. 950 2800 4600 1700 
TC † 1000 2100 720 
10 years implementation  
H-MIS † † † † 
H-MIS+NRT † 980 2100 600 
IC+NRT 1500 3800 6100 1900 
IC+Bupr. 800 2500 4300 1300 
TC † 760 1800 500 
75 years implementation 
H-MIS † † † † 
H-MIS+NRT 210 990 2000 310 
IC+NRT 2300 4000 5900 1000 
IC+Bupr. 1400 2700 4200 730 
TC 10 720 1600 240 
 
 
Table 11 shows the impact of the time horizon on life-years, QALYs and total costs as well as 
cost-effectiveness ratios. It gives results for three different time-horizons: 2000-2020, 2000-
2030 and 2000-2050, for the base-case permanent 75-year implementation scenario. For all 
time horizons, minimal GP counseling was a cost saving intervention. Cost-effectiveness 
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ratios became more favourable for a longer time period. For intensive counseling with 
Bupropion, costs per QALY gained ranged from about €13,000 for a time horizon of 20 years 
to about €3,900 for a time horizon of 50 years.  
Cost-effectiveness ratios of intervention scenarios compared to current practice for scenarios 
reaching 10% and 50% of all smokers rather than 25% did not differ much from the base-case 
estimates, due to a roughly similar change in both cost and effects. Total costs and effects 
were of course different.  
 
Table 11: Number of life-years and QALYs gained, total additional intervention costs, total savings, and 
cost-effectiveness: costs per life-year gained and costs per QALY gained for the 75 years increased 
implementation scenario cumulative for different time periods, discounted at 4% for both costs and effects 
(EURO, year 2000 price level). 
Intervention LYs gained 
(*104) 
QALYs 
gained 
(*104) 
Intervention 
costs (*109) 
Cost savings of 
treatment for 
diseases (*109) 
Costs per 
LY gained 
Costs per 
QALY gained 
Time horizon 20 years 
H-MIS 5.8 9.0 0.33 0.52 † † 
H-MIS+NRT 11 18 2.9 1.0 12,400 7,900 
IC+NRT 14 22 6.1 1.2 27,300 17,300 
IC+Bupr. 16 25 5.7 1.4 20,600 13,000 
TC 5.3 8.3 1.3 0.48 11,500 7,300 
Time horizon 30 years 
H-MIS 14 19 0.40 0.89 † † 
H-MIS+NRT 26 37 2.4 1.7 4,800 3,400 
IC+NRT 32 45 5.0 2.1 12,700 9,000 
IC+Bupr. 36 52 4.7 2.4 9,200 6,500 
TC 13 18 1.1 0.82 4,100 2,900 
Time horizon 50 years 
H-MIS 27 34 0.48 1.3 † † 
H-MIS+NRT 51 65 3.5 2.4 2,200 1,700 
IC+NRT 61 79 7.2 2.9 7,100 5,500 
IC+Bupr. 69 90 6.7 3.3 5,000 3,900 
TC 25 32 1.6 1.2 1,700 1,400 
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Conclusions and discussion 
 
The present study analyses the cost-effectiveness of five face-to-face smoking cessation 
interventions compared to current practice. Costs per life year gained for IC+NRT, H-
MIS+NRT,  IC+Bupr and TC are well below € 20.000. Costs per QALY are even lower. Only 
for H-MIS net savings accompany the health gains, because the savings from reduced costs of 
care for smoking related diseases offset the intervention costs. These results were robust for 
variations in the percentage of smokers reached, the duration of implementation, the resource 
use estimates and the cessation rates. The results were very sensitive to the rate of 
discounting.  
 
Comparing the results for the five interventions to each other, two interventions were 
relatively cheap: H-MIS and TC. But they were also less effective than the other 
interventions. The effectiveness of H-MIS in the Netherlands was based on a single trial. This 
was reflected in large uncertainty ranges. We choose this Dutch trial 33 instead of a Cochrane 
review on physician counseling 64, because we felt that the 11 studies on minimal counseling 
included in the review did not sufficiently reflect the Dutch H-MIS. 
 
Two other interventions, IC combined with either NRT or Bupr were more effective, but also 
more expensive. Although their respective cost-effectiveness ratios were higher than the ratios 
of H-MIS and TC, they remain very favourable. For these interventions, costs were more 
difficult to estimate, because there are great variations in the duration and intensity of IC and 
the duration of NRT use. 
 
One intervention, minimal counseling combined with NRT, fell in between. Its costs were 
highly uncertain, resulting in an uncertainty range that goes from slight cost savings up to 
high additional costs. This was in line with results from Cochrane reviews that state that the 
added effect of NRT to low intensity counseling was hard to prove. The trials included in the 
Cochrane reviews showed a high variance in the duration of NRT, mainly due to differences 
in compliance. It should be noted here that we combined nicotine patches and gums, although 
the evidence for the effectiveness of gums, especially when combined with low intensity 
counseling, is weaker. We focussed on nicotine patches and gum, because these are most 
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commonly used types of NRTs in the Netherlands and there is less published evidence on the 
effectiveness of nicotine inhalers and tablets. 
 
Figures 1 and 2 showed that it took 15 to 20 years before the reduction in the incidence of 
smoking related diseases became substantial. Therefore, on the short term, cost-effectiveness 
ratios reached values close to € 20000. However, when the time horizon is long enough to 
capture the effects of smoking cessation, cost-effectiveness ratios are well below the € 20000 
limit. 
 
How favourable these cost-effectiveness ratios are is best demonstrated by comparing them to 
other preventive interventions. For example, the Dutch 1998 cholesterol guidelines advise to 
reimburse cholesterol lowering treatment up to NLG 40,000 per QALY7,8. A US study 
published in 2000, found the costs per QALY of cholesterol lowering therapies to range from 
US$ 5,4000 to US$ 1,400,000 depending on patient characteristics.72 An Australian study 
from 1991, found the cost per QALY of pharmacological hypertension treatments to range 
from UK£ 11,058 to UK£ 194,989.73  
 
In contrast with most cost-effectiveness analyses of smoking cessation, we took cost savings 
of avoided smoking-related diseases into account. If we would assess the cost-effectiveness of 
permanent introduction (i.e. 75 year implementation), and ignore these savings in the costs of 
care for smoking-related diseases, the costs per life-year gained would vary from about € 
1,600 for H-MIS to € 10,500 for IC combined with NRT.  
 
Our study differs from others in another aspect. Our model is dynamic and takes account of 
relapse rates. Hence, not all smokers who quit in the 1-year scenario would remain non-
smokers for the whole time horizon. This led to higher cost-effectiveness ratios than we 
would have obtained if we had ignored relapse. 
 
Comparing our ratios with those of a recently published cost-effectiveness analysis in the 
United Kingdom 10, care must be taken to compare the right scenarios. Our results refer to 
interventions that were implemented on a continuous basis (repeated every year) for 1, 10 and 
75 years and adopted time horizons of 20, 30, 50 and 75 years. Parrott et al assumed a once-
only implementation with a time horizon of 40 years and reported undiscounted costs per life 
year saved from the health authority perspective. These were £112, and £173 for brief advice, 
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and brief advice+self-help+NRT, respectively. If we take our one-year scenario with a time 
horizon of 40 years H-MIS, H-MIS+NRT, and TC were cost saving and costs per life year 
gained for IC+NRT and IC+Bupr were about €2100 and €1100, respectively. However, many 
factors render international comparison of cost-effectiveness results difficult (see Drummond 
and Pang66). In this case, we need to point at differences in the contents of the interventions 
and in modelling. For example, we included relapse rates for quitters, whereas Parrott et al did 
not. Despite this, the low costs per life year gained from Parrott et al. are close to our cost 
savings for H-MIS and H-MIS+NRT. 
 
Health care costs unrelated to smoking in life years gained from smoking cessation were 
ignored in our computations. Whether or not costs of care for diseases not related to smoking 
(so-called unrelated medical costs) should be included in cost-effectiveness analyses is a topic 
of discussion in the literature (see e.g. Drummond65,p57). In practice, most cost-effectiveness 
analyses exclude these costs, for reasons of data availability. The Dutch guideline for 
economic evaluations 63 advises to exclude unrelated medical costs. For that reason, in the 
present study these costs were also excluded so that the results can be compared to other cost-
effectiveness analyses. 
 
A complicating factor in comparing the results for the five interventions to each other is that 
the cessation rates used came from different trials and meta-analyses with different patient 
groups and comparators. We had to assume that the absolute cessation rates in the meta-
analyses and trials were valid for our mixed population of all smokers in the Netherlands. In 
reality, different smoking cessation interventions are offered to different types of smokers. 
Therefore, since the cost-effectiveness ratios for the high intensity interventions were still 
low, the study results cannot be interpreted as a support for discouraging the use of the high 
intensity interventions.  
 
For several reasons our results are conservative. The effects of smoking cessation on the 
course of disease were not included, nor were the effects of passive smoking, and the effects 
of smoking cessation by pregnant women on the health of their future infants. Furthermore, 
savings from reduced productivity losses were not included. A Dutch study estimated that the 
productivity gains of a quitter would be about € 105 per quitter per year in the long run67. If 
this figure were multiplied with, for example, the number of additional quitters generated by a 
1-year implementation of H-MIS+NRT than the productivity gains would be € 11.6 million 
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per year. Finally it should be noted that a large part of the future effects of the intervention 
efforts during the last 15-20 years of the permanent implementation scenario were not taken 
into account, because these health gains did not occur within the time horizon.  
 
In contrast, two reasons why our results may somewhat overestimate cost-effectiveness ratios 
must be mentioned. The first is that the estimates of effectiveness were obtained from clinical 
trials. If trial populations were a selection of motivated smokers, our cessation rates would be 
too high. This applies in particular to the more intensive interventions and to a less extend to 
the H-MIS(+NRT) and TC, because for the latter interventions, trials were often done in an 
unselected group of smoking GP patients. The second is that the model did not include a 
delay effect of smoking cessation, i.e. all quitters got the lower relative risks of disease 
incidence of former smokers the year after quitting. However, the estimates of the relative 
risks in our model were conservative. Relative risks of former smokers were estimated as an 
average of the relative risks of all former smokers regardless of how long ago they had 
stopped. This implies that for the first years after quitting the reduction in relative risk in our 
model is too high, while for later years it is too low. This simplification will have the largest 
impact on the elderly. Because the incidence of smoking related disease among older smokers 
is high the effects of smoking cessation in the subgroup of older smokers may be 
overestimated. Therefore, our finding that smoking cessation interventions become more cost 
effective when targeted at older age groups (all interventions were cost saving for the age 
group of 65 years and older) should be interpreted with care. 
 
In conclusion, when assessing the cost-effectiveness of five face to face smoking cessation 
interventions, we found that H-MIS was cost saving compared to current practice, whereas the 
cost-effectiveness ratios of minimal counseling plus nicotine replacement therapy, intensive 
counseling with nicotine replacement therapy, intensive counseling with bupropion, and 
telephone counseling were quite small. Implementation of  these interventions on a permanent 
basis for an additional 25% of all smokers, resulted in estimated cost-effectiveness ratios that 
varied from € 1100 to € 4900 per QALY.  
 
Instead of offering the smoking cessation interventions on a permanent basis, decision makers 
can opt for a much shorter period. This reduces the intervention costs considerably, but still 
produces important health gains and savings resulting from a reduced incidence of smoking-
related disease. However, it is obvious that these gains and savings become much smaller as 
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the implementation period is reduced. The cost-effectiveness ratios are not very much affected 
by the choice of the implementation period.  
This information is useful for politicians, healthcare insurers and healthcare providers in their 
efforts to reduce smoking prevalence.  
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Appendix A Short review of cost-effectiveness results for smoking cessation 
interventions in the literature. 
 
A literature search was performed to identify economic evaluations of smoking cessation 
interventions. The 18 relevant economic evaluations selected are summarized in tables A1 and 
A2.10,12-24,68-71 Two recent international systematic reviews of cost-effectiveness of smoking 
cessation interventions also discussed many of these studies.9,10 The transferability of results 
from foreign economic studies is difficult (see for example Drummond and Pang66). The 
numbers given in the tables and below were simply converted from figures in foreign 
currencies using Purchasing Power Parity data11 and then updated to the year 2000 with the 
help of consumer price indices, and should therefore be interpreted with care. Ultimately, the 
health outcomes of smoking cessation interventions are gains in morbidity and mortality from 
smoking related diseases. To find these, modeling has to be used to translate cessation rates 
into life-years or QALYs gained. An intermediary outcome often used in cost-effectiveness 
analyses is the number of quitters. Costs per life-year gained varied from €215 to €10.380 
with the majority of studies reporting cost-effectiveness ratios around €2500 per life-year 
gained. Most studies focussed on intervention costs only. Few cost-effectiveness studies 
included savings in costs for avoided smoking-related diseases.  
Dutch cost-effectiveness studies for smoking cessation were scarce. We could identify only 
one study, which reported costs per quitter for a group program plus self help cessation 
manual.24  
 
Conclusion: Smoking cessation interventions are cost-effective in general. Based on the 
international literature, taking account of the pitfalls involved in transferring international 
results, it seems safe to conclude that smoking cessation interventions fall well below the 
€20000 per QALY limit.
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Table A1. Overview of cost-effectiveness ratio’s per life years saved or QALYs saved in EUROs (price level 2000; 
societal perspective) 
Study smoking cessation 
intervention(s) 
Ratio compared to usual 
care, no intervention or 
placebo 
Ratio for other comparator 
than usual care, no 
intervention or placebo 
Comparator  
1. Brief advice €5097 * 16  
€215 10 
  
Brief advice + self-help €417 10   
Brief advice + NRT Patches: €2475 
Gum: €5851 * 16  
€10 380 ** ## 19 Brief advice only 
Brief advice + self-help + NRT €1507 10    
2. Intensive counseling (IC) €2362 * 16    
IC+ self-help €250 ** 17  
€4096 **** 18 
1. €574 ** 22 
2. €1947##  68 
 
1. Brief advice 
2. Brief 
advice+self help  
IC + NRT Patches: €2006  
Gum: €6200 *16  
 
€5044 (QALY)   * ## 14 
 €2559 * ##  23  
€5276 **  13 
€1780 ** 12  
Patches: €7638 ###  
Gum: €5596 ###  20 
IC alone 
IC + self-help + NRT  €648 ** #  21 IC +self help 
3. Group program (GP) €1657 *16    
GP + NRT Patches: €1568  
Gum: €2579 * 16  
  
4. Specialist smoking service    
Specialist smoking service: brief 
advice + self-help + NRT 
€1358 10   
Specialist smoking service: IC+ group 
program + NRT 
€3840 ** 69   
* Perspective of patients/smokers; ** Perspective of third party payers/NHS; *** Perspective of employers; **** Perspective 
of implementing hospital 
# Aged 45-54; ##    Aged 45-49; ###  Aged 40-49 
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Table A2. Overview of cost-effectiveness ratio’s per quitter in EUROs (price level 2000; societal 
perspective) 
Study smoking cessation 
intervention(s) 
Ratio compared to usual 
care, no intervention or 
placebo. 
Ratio for other comparator 
than usual care, no 
intervention or placebo  
Comparator.  
1. Self-help (see also 3) €856 * 24   
2.  Brief advice €133  15   
3. Intensive counseling (IC) €939  15   
IC + self-help €431 ** 17 
€4114 **** 18 
€1276 **  22 Brief advice 
IC + NRT €1032 * 70 
 
€1460 **  13 
€892 ** 12 
Intensive counseling 
IC + self-help + NRT €520 71   
4. Group program (GP) €230 * 24 
€1661 15  
  
* Perspective of patients/smokers; ** Perspective of third party payers/NHS; *** Perspective of employers; **** 
Perspective of implementing hospital 
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